Trial · NCT02201251
Outcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Weight Z-score up to Month 1 | Baseline up to Month 1 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. | Z-score | MEAN |
| PRIMARY | Change From Baseline in Weight Z-score up to Month 3 | Baseline up to Month 3 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. | Z-score | MEAN |
| PRIMARY | Change From Baseline in Weight Z-score up to Month 6 | Baseline up to Month 6 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. | Z-score | MEAN |
| PRIMARY | Change From Baseline in Weight Z-score up to Month 9 | Baseline up to Month 9 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. | Z-score | MEAN |
| PRIMARY | Change From Baseline in Weight Z-score up to Month 12 | Baseline up to Month 12 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. | Z-score | MEAN |
| PRIMARY | Change From Baseline in Height Z-score up to Month 1 | Baseline up to Month 1 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. | Z-score | MEAN |
| PRIMARY | Change From Baseline in Height Z-score up to Month 3 | Baseline up to Month 3 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. | Z-score | MEAN |
| PRIMARY | Change From Baseline in Height Z-score up to Month 6 | Baseline up to Month 6 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. | Z-score | MEAN |
| PRIMARY | Change From Baseline in Height Z-score up to Month 9 | Baseline up to Month 9 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. | Z-score | MEAN |
| PRIMARY | Change From Baseline in Height Z-score up to Month 12 | Baseline up to Month 12 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. | Z-score | MEAN |
| PRIMARY | Change From Baseline in Bone Mineral Density (BMD) Z-score up to Month 6 | Baseline up to Month 6 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies the number of participants evaluable for this outcome measure. Here, 'n' (number analyzed) signifies the number of participants evaluable for specified categories. | Z-score | MEAN |
| PRIMARY | Change From Baseline in BMD Z-score up to Month 12 | Baseline up to Month 12 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies the number of participants evaluable for this outcome measure. Here, 'n' (number analyzed) signifies the number of participants evaluable at a specified category. | Z-score | MEAN |
| PRIMARY | Change From Baseline in Bone Mineral Content (BMC)-Z Score up to Month 6 | Baseline up to Month 6 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies the number of participants evaluable for this outcome measure. Here, 'n' (number analyzed) signifies the number of participants evaluable at a specified category. | Z-score | MEAN |
| PRIMARY | Change From Baseline in BMC-Z Score up to Month 12 | Baseline up to Month 12 | The safety analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies the number of participants evaluable for this outcome measure. Here, 'n' (number analyzed) signifies the number of participants evaluable at a specified category. | Z-score | MEAN |
| SECONDARY | Number of Participants With Treatment-emergent Adverse Events (TEAE) | Up to Day 390 | Safety analysis set included all randomized participants who received at least 1 dose of study treatment. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Participants With Kidney Stones | Up to Day 390 | Safety analysis set included all randomized subjects who received at least 1 dose of study treatment. | percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02201251/outcomes